Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + Docetaxel in HER2+ Advanced Breast Cancer
NCT01044485Phase 2Completed
- Sponsor
- Centre Georges-François Leclerc
- Start
- Nov 2008
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in HER2-positive breast cancer, sponsored by Centre Georges-François Leclerc. Started Nov 2008; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01044485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01044485.